2The role of biomarkers in the assessment of lupus
Section snippets
Introduction: challenges in assessing efficacy of SLE treatment
The greatest challenge to drug development in SLE has been its unpredictability, which makes treatment selection and outcome measurement intrinsically problematic. Several formally validated measures of lupus disease activity are now available for use, which combine complex assessments of varying manifestations in attempts to compare outcomes among diverse patients. These instruments are described in detail in Chapter 1 and include the SLAM (Systemic Lupus Activity Measure), SLEDAI (Systemic
An emerging field, candidate biomarkers for the guidance of therapy for SLE
The availability of validated biologic markers in SLE will be an important advance in the assessment of new treatments for SLE and optimization of their use. A credible set of biomarkers might predict whether a given patient is appropriate for a treatment and quantify their disease activity before, during and after treatment, and hence guide therapy. Some promising candidates might additionally work as surrogate endpoints (defined as markers that are detected early in the course of therapy but
The need for a cooperative international effort to validate SLE biomarkers
The major impediments to successful drug development for lupus will be solved when the development community can successfully integrate emerging knowledge about the nature of the immune dysfunction with adequate definitions of disease flare and remission. A critical component of this process will be the validation and strategic employment of a comprehensive set of biologic markers to optimize administration of investigational, immune-modulating agents and to assess their effectiveness. Methods
References (96)
- et al.
The bimodal mortality in systemic lupus erythematosus
The American Journal of Medicine
(1976) - et al.
Generation of C-reactive protein and complement components in atherosclerotic plaques
The American Journal of Pathology
(2001) - et al.
Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C or protein S: an explanation for their pathogenic mechanism?
Blood
(1993) MRC1q Daha as antigen in humoral autoimmune responses
Immunobiology
(1998)- et al.
Crossreaction between antibodies to oxidized low density lipoprotein and to cardiolipin in systemic lupus erythematosus
Lancet
(1993) - et al.
Immune complexes and IFN-gamma decrease cholesterol 27-hydroxylase in human arterial endothelium and macrophages
Journal of Lipid Research
(2001) - et al.
Aberrant expression of the costimulatory molecule CD40 ligand on monocytes from patients with systemic lupus erythematosus
Clinical Immunology
(2002) - et al.
Innate immune mechanisms in the pathogenesis of systemic lupus erythematosus (SLE)
Immunology Letters
(2001) - et al.
Intravascular neutrophil activation in systemic lupus erythematosus (SLE): dissociation between increased expression of CD11b/CD18 and diminished expression of L-selectin on neutrophils from patients with active SLE
Clinical Immunology Immunopathol
(1994) - et al.
Impaired production of IL-12 in systemic lupus erythematosus. I. Excessive production of IL-10 suppresses production of IL-12 by monocytes
Cytokine
(1998)
A novel polymorphism in the Fcgamma receptor IIB (CD32B) transmembrane region alters receptor signaling
Arthritis and Rheumatism
Frequency of the Fc gamma RIIIA-158F allele in African American patients with systemic lupus erythematosus
The Journal of Rheumatology
CD72 polymorphisms associated with alternative splicing modify susceptibility to human systemic lupus erythematosus through epistatic interaction with FCGR2B
Human Molecular Genetics
Indicators of disease activity, prognosis, and treatment of systemic lupus erythematosus
Current Opinion in Rheumatology
Sensitivity to change of 3 systemic lupus erythematosus disease activity indices: international validation
The Journal of Rheumatology
index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus
Quartely Journal of Medicine
Crosscultural validation and reliability of 3 disease activity indices in systemic lupus erythematosus
The Journal of Rheumatology
Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research III
Clinical and Experimental Rheumatology
Comparison of the validity and sensitivity to change of 5 activity indices in systemic lupus erythematosus
The Journal of Rheumatology
Responsiveness and sensitivity to change of SLE disease activity measures
Lupus
Sensitivity of the systemic lupus erythematosus disease activity index, British isles lupus assessment group index, and systemic lupus activity measure in the evaluation of clinical change in childhood-onset systemic lupus erythematosus
Arthritis and Rheumatism
Estrogen/Cyclic progesterone replacement is associated with an increased rate of mild/moderate but not severe flares in SLE patients in the SELENA trial
Arthritis and Rheumatism
Biomarkers in systemic lupus erythematosus. I. General overview of biomarkers and their applicability
Arthritis and Rheumatism
Biomarkers in systemic lupus erythematosus. II. Markers of disease activity
Arthritis and Rheumatism
Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies
Lupus
Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus
Science
Serum levels of interferons in patients with systemic lupus erythematosus
Clinical and Experimental Immunology
Interferon and natural killer cells in systemic lupus erythematosus
Clinical and Experimental Immunology
Patients with systemic lupus erythematosus (SLE) have a circulating inducer of interferon-alpha (IFN-alpha) production acting on leucocytes resembling immature dendritic cells
Clinical and Experimental Immunology
Serum interferon levels in patients with systemic lupus erythematosus
Arthritis and Rheumatism
Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus
Proceedings of the National Academy of Sciences of the United States of America
Interferon and granulopoiesis signatures in systemic lupus erythematosus blood
The Journal of Experimental Medicine
Complement and systemic lupus erythematosus
Arthritis Res
Update on complement in the pathogenesis of systemic lupus erythematosus
Current Opinion in Rheumatology
The spectrum of vasculitis
Annual Internationa Medicine
Significance of serum complement levels for diagnosis and prognosis of acute and subacute glomerulonephritis and lupus erythematosus disseminatus
Annual International Medicine
Human complement metabolism: an analysis of 144 studies
Medicine (Baltimore)
Studies of the in vitro behavior of human C′3 in normal subjects and patients
The Journal of Clinical Investigation
Decreased synthesis of the third component (C3) in hypocomplementemic systemic lupus erythematosus
Clinical and Experimental Immunology
Metabolic studies of the third component of complement and the glycine rich glycoprotein in patients with hypocomplementemia
The Journal of Clinical Investigation
Quantitative and antigenic differences in complement component C4 between American blacks and whites
Complement Inflammation
Increased levels of plasma anaphylatoxins in systemic lupus erythematosus predict flares of the disease and may elicit vascular injury in lupus cerebritis
Arthritis and Rheumatism
Assessment of disease activity and impending flare in patients with systemic lupus erythematosus. Comparison of the use of complement split products and conventional measurements of complement
Arthritis and Rheumatism
Usefulness of detection of complement activation products in evaluating SLE activity
Lupus
Measurement of erythrocyte C4d and complement receptor 1 in systemic lupus erythematosus
Arthritis and Rheumatism
Age-specific incidence rates of myocardial infarction and angina in women with Systemic Lupus Erythematosus: comparison with the Framingham study
The American Journal of Epidemiology
Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus
Arthritis and Rheumatism
Complement components, but not complement inhibitors, are upregulated in atherosclerotic plaques
Arteriosclerosis, Thrombosis, and Vascular Bioliogy
Cited by (27)
Urinary TWEAK and the activity of lupus nephritis
2006, Journal of AutoimmunityCitation Excerpt :These criteria may include certain ethnicities, particular systemic disease involvement, or certain genetic characteristics. The SLE Disease Activity Index is considered a simple and reliable tool in documenting disease activity [20,23], yet some studies show that it is not very sensitive to change [37]; therefore, the SLEDAI may not be sufficiently accurate for stand-alone use. It is encouraging that in a few patients (a representative case is presented in Fig. 5C), uTWEAK levels changed in accordance with the patients' disease activity as defined by the sensitive OSS criteria, while the rSLEDAI remained constant.
Serum cystatin C and βeta-2 microglobulin as potential biomarkers in children with lupus nephritis
2023, Archives of RheumatologyModulatory Effect of the Euro-Lupus Low-Dose Intravenous Cyclophosphamide Regimen on Circulating Immune Cells in Systemic Lupus Erythematosus
2019, Archivum Immunologiae et Therapiae ExperimentalisClinical response beyond the systemic lupus erythematosus responder index: Post-hoc analysis of the BLISS-SC study
2018, Lupus Science and Medicine